This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Catalog
ASAP is committed to accelerating the pace of discovery and informing a path to a cure for Parkinson’s disease through collaboration, research-enabling resources, and data sharing. We’ve created this catalog to showcase the research outputs and tools developed by ASAP-funded programs.
Article
Three-step docking by WIPI2, ATG16L1 and ATG3 delivers LC3 to the phagophore: Molecular dynamics simulation dat
Atomistic molecular dynamics simulation data set accompanying manuscript “Three-step docking by WIPI2, ATG16L1 and ATG3 delivers LC3 to the phagophore.”
Teams
Article
Peripheral MC1R activation modulates immune responses and is neuroprotective in a mouse model of Parkinson’s disease
Preprint: The present study investigates the impact of NDP-MSH, a synthetic melanocortin receptor (MCR) agonist that does not cross BBB, on the immune system and the nigrostriatal dopaminergic system in mouse model of PD.
Teams
Article
DOPA pheomelanin is increased in nigral neuromelanin of Parkinson’s disease
Published: Neuromelanin in the substantia nigra may be a key factor contributing to dopaminergic neuron vulnerability in Parkinson’s disease. Neuromelanin consists of pheomelanin and eumelanin moieties. Here, authors investigated the relative composition and specific roles of pheomelanin and eumelanin moieties of NM in PD. View original preprint.
Teams
Article
Melanocortin 1 receptor activation protects against alpha-synuclein pathologies in models of Parkinson’s disease
Publication: The authors previously showed that MC1R signaling can facilitate nigrostriatal dopaminergic neuron survival. The present study investigates the neuroprotective potential of MC1R against neurotoxicity induced by alpha-synuclein, a key player in PD genetics and pathogenesis. View original preprint.
Teams
Article
Parkinson’s disease and cancer: a systematic re and meta-analysis of over 17 million participants
Published: The authors examined risk association between Parkinson’s disease and cancer using data from 63 publications, totaling in 17 million individuals. With the exception of melanoma, the authors found that the risk association of Parkinson’s disease and cancer was inversely related.
Teams
Article
LRRK2 G2019S mutation suppresses differentiation of Th9 and Treg cells via JAK/STAT3
The Leucine-rich repeat kinase-2 (LRRK2) G2019S mutation is one of the well-recognized genetic risk factors in Parkinson’s disease (PD). Increased LRRK2 activity was also observed in immune cells from PD patients. The authors generated and characterized a new T cell receptor (TCR) transgenic mouse strain bearing LRRK2 G2019S knock-in mutation.
Teams
Article
Oncogenic BRAF V600E induces glial proliferation through ERK and neuronal death through JNK
Activating V600E in BRAF is a common driver mutation in cancers of multiple tissue origins. BRAF V600E has also been implicated in neurodegeneration. The present study aims to characterize BRAF V600E on cell death and survival in three major cell types of the CNS: neurons, astrocytes, and microglia.
Teams